Using this technique, levels of S100A6 were found to be statistically elevated in the sera of women with advanced stage disease compared to those with early stage tumors (p = 0.031), demonstrating an association between clinical features of greater tumor burden and increased levels of S100A6 in OVCA patients (Figure 7). Here, S100A6 is linked to neoplasm.